Enhanced Next Generation Millimeter-Wave Multicarrier System with Generalized Frequency Division Multiplexing

Orthogonal Frequency Division Multiplexing (OFDM) is a popular multicarrier technique used to attain high spectral efficiencies. It also has other advantages such as multipath tolerance and ease of implementation. However, OFDM based systems suffer from high Peak-to-Average Power Ratio (PAPR) problem. Because of the nonlinearity of the power amplifiers, the high PAPR causes significant distortion in the transmitted signal for millimeter-wave (mmWave) systems. To alleviate the high PAPR problem, this paper utilizes Generalized Frequency Division Multiplexing (GFDM) which can achieve high spectral efficiency as well as low PAPR. In this paper, we show the performance of GFDM using the IEEE 802.11ad multicarrier frame structures. IEEE 802.11ad is considered one of the most successful industry standards utilizing unlicensed mmWave frequency band. In addition, this paper indicates the feasibility of using GFDM for the future standards such as IEEE 802.11ay. This paper studies the performance improvements in terms of PAPR reduction for GFDM. Based on the performance results, the optimal numbers of subcarriers and subsymbols are calculated for PAPR reduction while minimizing the Bit Error Rate (BER) performance degradation. Moreover, transmitter side ICI (Intercarrier Interference) reduction is introduced to reduce the receiver load

Millimeter-wave Evolution for 5G Cellular Networks

Triggered by the explosion of mobile traffic, 5G (5th Generation) cellular network requires evolution to increase the system rate 1000 times higher than the current systems in 10 years. Motivated by this common problem, there are several studies to integrate mm-wave access into current cellular networks as multi-band heterogeneous networks to exploit the ultra-wideband aspect of the mm-wave band. The authors of this paper have proposed comprehensive architecture of cellular networks with mm-wave access, where mm-wave small cell basestations and a conventional macro basestation are connected to Centralized-RAN (C-RAN) to effectively operate the system by enabling power efficient seamless handover as well as centralized resource control including dynamic cell structuring to match the limited coverage of mm-wave access with high traffic user locations via user-plane/control-plane splitting. In this paper, to prove the effectiveness of the proposed 5G cellular networks with mm-wave access, system level simulation is conducted by introducing an expected future traffic model, a measurement based mm-wave propagation model, and a centralized cell association algorithm by exploiting the C-RAN architecture. The numerical results show the effectiveness of the proposed network to realize 1000 times higher system rate than the current network in 10 years which is not achieved by the small cells using commonly considered 3.5 GHz band. Furthermore, the paper also gives latest status of mm-wave devices and regulations to show the feasibility of using mm-wave in the 5G systems.Comment: 17 pages, 12 figures, accepted to be published in IEICE Transactions on Communications. (Mar. 2015

Phase II study of trifluridine/tipiracil (TAS‑102) therapy in elderly patients with colorectal cancer (T‑CORE1401): geriatric assessment tools and plasma drug concentrations as possible predictive biomarkers

Purpose The current study aimed to determine the efficacy of trifluridine/tipiracil for elderly patients with advanced colorectal cancer. Methods This single-arm, open-label, multicenter, phase II study included elderly patients aged 65 years or more who had fluoropyrimidine-refractory advanced colorectal cancer and received trifluridine/tipiracil (70 mg/m2, days 1–5 and 8–12, every 4 weeks). The primary endpoint was progression-free survival (PFS), while secondary endpoints included overall survival (OS), overall response rate (ORR), toxicities, association between efficacy and geriatric assessment scores, and association between toxicity and plasma drug concentrations. Results A total of 30 patients with a mean age of 73 years were enrolled. Median PFS was 2.3 months (95% confidence interval, 1.9–4.3 months), while median OS was 5.7 months (95% confidence interval, 3.7–8.9 months). Patients had an ORR of 0%, with 57% having stable disease. Grade 4 neutropenia was observed in 13% of the patients. Patients with a higher G8 score (15 or more) showed longer PFS than those with a lower G8 score (median 4.6 vs. 2.0 months; p = 0.047). Moreover, patients with grade 3 or 4 neutropenia showed higher maximum trifluridine concentrations than those with grade 1 or 2 neutropenia (mean 2945 vs. 2107 ng/mL; p = 0.036). Discussion The current phase II trial demonstrated that trifluridine/tipiracil was an effective and well-tolerated option for elderly patients with advanced colorectal cancer. Moreover, geriatric assessment tools and/or plasma drug concentration monitoring might be helpful in predicting the efficacy and toxicities in elderly patients receiving this drug. Trial registration number UMIN000017589, 15/May/2015 (The University Hospital Medical Information Network